Perioperative Safety Profile of IBD Medications: A Comparative Study of Real World Pharmacovigilance Data (ACG 2026) - Aug 29, 2026 - Abstract #P3401; Pres time: Oct 12, 2026; 10:30 AM - 04:15 PM; Location: Exhibit Halls A - D (Level 3); "Golimumab showed elevated UC sepsis (1.88), whereas Adalimumab and Certolizumab showed lower CD sepsis (0.54, 0.27) and Adalimumab lower DVT and PE in both indications. Vedolizumab showed elevated UC DVT and PE (~1.5); natalizumab elevated CD PE (2.30); ustekinumab an isolated UC ileus signal (14.15)... Thiopurines and Methotrexate showed the most consistent signals across both indications: elevated ROR for sepsis (Azathioprine UC: ROR 2.03, CD: 1.85; Mercaptopurine UC: 2.64, CD: 2.04; Methotrexate UC: 1.57), DVT (Methotrexate UC 4.15, CD 2.33; Azathioprine CD 2.23, Mercaptopurine UC 2.29), and PE (Methotrexate UC 1.96; Azathioprine CD 1.84). Azathioprine UC also showed elevated anastomotic leak (7.15). Among anti-TNFs, infliximab showed elevated CD sepsis (2.12), DVT (1.90), and PE (1.82), as well as UC DVT (1.32)."
Adverse events • Clinical • Real-world • Real-world evidence • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Septic Shock • Ulcerative Colitis
|
|
Parsia Vazirnia MD 1; Nick Adimi MD 2; Bradley Hartwyk BS 1; Valery Vilchez MD 3; Robert Fearn MD 3
|